Testing supplies are required to continue Newborn DNA Analysis testing as part of the Newborn Screening Program. Without these testing supplies, we…

Fisher Scientific Company LLC has been awarded a Texas state contract for providing testing supplies essential to the Newborn Screening Program's DNA Analysis testing capabilities. The contract, identified by HHSTX-6-386527, supports critical diagnostic testing for newborn disorders, with supplies classified under Laboratory consumables and chemicals (UNSPSC 41121822) and Laboratory Equipment (NIGP 17553). The procurement is specifically aimed at ensuring continuous testing capacity for identifying potential health conditions in newborns.

The contract is effective through September 30, 2025, and is crucial for maintaining uninterrupted diagnostic services. Without these testing supplies, the state would risk significant delays in diagnosing and treating newborns with potential genetic disorders, which could result in irreversible negative health impacts. While specific contract values were not detailed in the provided documentation, the award underscores the Texas health system's commitment to comprehensive newborn healthcare screening and early intervention strategies.